Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-711 + HCTZ in Hypertension
NCT00089713Phase 2Terminated
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alagebrium in hypertension (HTN) (4 arms), sponsored by Synvista Therapeutics, Inc. Primary endpoint: Systolic Blood Pressure. Started Mar 2004; status: terminated.
02
Drugs
alagebrium
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00089713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089713.